Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.
Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...
Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...
In the physiological condition of skeletogenesis (left), SSCs maintain a quiescent state for orderly differentiation which is regulated by the epigenetic signature. Especially at this state, ...
Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...
A naturally occurring mutation in T cells that leads to lymphoma can be weaponized to make engineered T-cell therapies more effective against cancer, including melanoma, findings from a new study in ...
Morning Overview on MSN
Disabling NFIL3 via CRISPR kept engineered CAR T-cells from hitting exhaustion, prolonging tumor control in animal models
Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the transcription factor NFIL3 in engineered CAR T cells, and the modified ...
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results